Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oligometastatic neuroendocrine tumors: characteristics and prognosis.

British journal of cancer·2026

Same author

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026

Same author

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

HemaSphere·2026

Same author

B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer.

Endocrine-related cancer·2026

Same author

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review.

Blood reviews·2026

Same author

Patient characteristics and prognostic factors in advanced treatment lines in metastatic neuroendocrine tumors.

Journal of endocrinological investigation·2026

Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026

Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026

Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026

Same journal

Precision Transfusion Medicine in the Omics Era.

Blood·2026

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 26, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

A MALT lymphoma prognostic index.

Catherine Thieblemont¹, Luciano Cascione^2,3, Annarita Conconi^3,4

¹Assistance Publique-Hôpitaux de Paris Hemato-Oncology Department, Saint Louis Hospital, Diderot University-Sorbonne Paris Cité, Paris, France.

|July 20, 2017

Summary

This summary is machine-generated.

A new prognostic index, the MALT-lymphoma International Prognostic Index (MALT-IPI), identifies patients with mucosa-associated lymphoid tissue (MALT) lymphoma at high risk for poor outcomes. This tool uses age, Ann Arbor stage, and lactate dehydrogenase levels to guide personalized treatment strategies.

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Related Experiment Videos

Last Updated: Feb 26, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Area of Science:

Hematology
Oncology
Clinical Research

Background:

Prognostic indices for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) are lacking.
Personalized treatment strategies require validated prognostic tools for MALT lymphoma patients.

Purpose of the Study:

To develop and validate a specific prognostic index for MALT lymphoma.
To identify key prognostic factors for event-free survival (EFS) in MALT lymphoma.

Main Methods:

Cox regression analysis was used to build the prognostic index from 401 patients in the IELSG-19 trial.
The index was validated using a merged dataset of 633 patients from independent cohorts.
Key prognostic factors identified were age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase.

Main Results:

The MALT-lymphoma International Prognostic Index (MALT-IPI) was developed using age, Ann Arbor stage, and lactate dehydrogenase.
MALT-IPI stratified patients into low, intermediate, and high-risk groups with distinct 5-year EFS rates (70%, 56%, 29%).
The index demonstrated significant prognostic utility for progression-free, overall, and cause-specific survival across various subgroups and was validated in independent cohorts.

Conclusions:

The MALT-lymphoma International Prognostic Index (MALT-IPI) is a simple, accessible, and effective tool for identifying MALT lymphoma patients with poor prognoses.
MALT-IPI can aid in personalizing treatment approaches for individual MALT lymphoma patients.